GSK
NEUTRALGSK CEO Granted Top-Up Performance Share Award
The healthcare company has granted its CEO a top-up conditional share award under the firm's performance share plan.
GSK
1,379.70GBX
1.15%
Market Cap
59.63B
Volume
743.98k
7% of avg
P/E Ratio
8.21
EPS (TTM)
1.68
Beta
0.27
Day Range
1,376.53p - 1,387.50p
52 Week Range
1,242.50p1,379.70p1,823.50p
1,379.70p
Upcoming Events
GSK
NEUTRALGSK Announces Director/PDMR Shareholding
The healthcare company has announced a director's shareholding transaction.
GSK
GOODGSK's Linerixibat Meets Primary Endpoint in PBC Pruritus Trial
The pharmaceutical company announced positive results from a phase III trial of its drug linerixibat for treating cholestatic pruritus in primary biliary cholangitis patients.
GSK
NEUTRALGSK Announces Director Appointment
The healthcare company has announced the appointment of a new director to its board.
GSK
NEUTRALGSK's Nucala shows promise in reducing COPD exacerbations
The pharmaceutical company reports positive results from a phase III trial of its Nucala drug in treating chronic obstructive pulmonary disease.
GSK
GOODGSK Reports Strong Q1 2025 Results, Reaffirms Full-Year Guidance
The major pharmaceutical company reported solid Q1 2025 results, with moderate revenue growth and strong cash generation. The firm reaffirmed its full-year guidance, signaling confidence in its performance.
GSK
GOODGSK's Blenrep Combinations Approved by UK MHRA for Relapsed/Refractory Multiple Myeloma
The healthcare company has received UK regulatory approval for its Blenrep combinations to treat relapsed/refractory multiple myeloma, marking the first such approval globally.
GSK
NEUTRALGSK Directors Increase Shareholdings
The retailer has announced changes to its senior leadership team, with the appointment of a new Chief Operating Officer.
GSK
NEUTRALGSK's RSV vaccine Arexvy recommended for 50-59 at-risk adults
The healthcare company announces that its RSV vaccine Arexvy has been recommended for use in adults aged 50-59 who are at increased risk.
GSK
NEUTRALGSK's 5-in-1 meningitis vaccine recommended in US
The healthcare company announced that its 5-in-1 meningococcal vaccine has received a positive recommendation from the US Advisory Committee on Immunization Practices.